Richter A, Löschmann P A, Löscher W
Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine, Hannover, Germany.
Br J Pharmacol. 2000 Nov;131(5):921-6. doi: 10.1038/sj.bjp.0703609.
In a hamster model (genetic symbol dt(sz)) of primary paroxysmal non-kinesiogenic dystonic choreoathetosis, recent studies have shown beneficial effects of glutamate and dopamine receptor antagonists. Nitric oxide (NO), synthesized from L-arginine by NO synthase in response to glutamate receptor activation, elicits cyclic GMP and modulates glutamate-mediated processes and striatal dopamine release. Therefore, the effects of NO synthase inhibitors and of L-arginine on severity of dystonia were investigated in dt(sz) hamsters in which dystonic attacks, characterized by twisting movements and postures, can be induced by stress. The NO synthase inhibitors N(G)-nitro-L-arginine (L-NNA), N(G)-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole significantly reduced the severity of dystonia. At antidystonic effective doses neither L-NNA nor L-NAME caused observable side effects, whereas 7-nitroindazole exerted moderate reduction of locomotor activity. The antidystonic effect of L-NAME was reversed by co-administration of the NO precursor L-arginine. However, L-arginine administered alone did not exert any effect on severity of dystonia. Cerebellar cyclic GMP levels in brains of mutant hamsters in comparison to non-dystonic control hamsters did not significantly differ, but the cerebellar cyclic GMP levels tended to be increased in dt(sz) hamsters during a dystonic attack. L-NAME significantly decreased the cerebellar cyclic GMP levels in both dt(sz) and control hamsters. Although an overproduction of NO is probably not critically involved in the pathogenesis of paroxysmal dystonia, it may contribute to the manifestation of dystonic attacks, as indicated by the antidystonic effects of NO synthase inhibitors. Peripheral side effects may limit the clinical use of NO synthase inhibitors, but more selective inhibitors of the neuronal NO synthase should be considered as interesting candidates for the treatment of paroxysmal dystonia.
在原发性阵发性非运动诱发性肌张力障碍性舞蹈手足徐动症的仓鼠模型(基因符号dt(sz))中,近期研究显示谷氨酸和多巴胺受体拮抗剂具有有益作用。一氧化氮(NO)由一氧化氮合酶响应谷氨酸受体激活从L-精氨酸合成,可引发环磷酸鸟苷(cGMP)并调节谷氨酸介导的过程以及纹状体多巴胺释放。因此,在dt(sz)仓鼠中研究了一氧化氮合酶抑制剂和L-精氨酸对肌张力障碍严重程度的影响,在该模型中,由扭转运动和姿势所表征的肌张力障碍发作可由应激诱发。一氧化氮合酶抑制剂N(G)-硝基-L-精氨酸(L-NNA)、N(G)-硝基-L-精氨酸甲酯(L-NAME)和7-硝基吲唑显著降低了肌张力障碍的严重程度。在抗肌张力障碍有效剂量下,L-NNA和L-NAME均未引起可观察到的副作用,而7-硝基吲唑使运动活性有适度降低。L-NAME的抗肌张力障碍作用可通过共同给予NO前体L-精氨酸而逆转。然而,单独给予L-精氨酸对肌张力障碍严重程度未产生任何影响。与非肌张力障碍对照仓鼠相比,突变仓鼠脑内小脑cGMP水平无显著差异,但在肌张力障碍发作期间,dt(sz)仓鼠小脑cGMP水平有升高趋势。L-NAME显著降低了dt(sz)仓鼠和对照仓鼠的小脑cGMP水平。尽管NO的过量产生可能并非阵发性肌张力障碍发病机制的关键因素,但如一氧化氮合酶抑制剂的抗肌张力障碍作用所示,其可能促成肌张力障碍发作的表现。外周副作用可能会限制一氧化氮合酶抑制剂的临床应用,但神经元一氧化氮合酶的更具选择性的抑制剂应被视为治疗阵发性肌张力障碍的有吸引力的候选药物。